A comparative review of conventional and lipid formulations of amphotericin B.
Over the past 15 years, factors suh as corticosteroid treatment, cytotoxic chemotherapy, excessive use of broad spectrum antibiotics and HIV have led to an increased risk of serious fungal infections in both adults and pediatric patients. This increase in invasive fungal infections poses increasing difficulty in their treatment. Three new lipid formulations of amphotericin B are now available in the U.S.: amphotericin B lipid complex (Abelcet), amphotericin B colloidal dispersion (Amphotec), and liposomal amphotericin B (AmBisome). These newer formulations are substantially more expensive, but allow patients to receive higher doses for longer periods of time with decreased renal toxicity than conventional amphotericin B. The properties of these new agents are summarized in this review. Discussion of current national guidelines as well as those used at our institution are presented to provide guidance for the development of institution specific guidelines for the most cost-effective drug for most patients, some may benefit more from one of the newer lipid formulations.
Robinson
R F
RF
Department of Pharmacy, Children's Hospital and College of Pharmacy, Ohio State University, Columbus, USA.
Nahata
M C
MC
D000666:Amphotericin B / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002626:Chemistry, Pharmaceutical; D006801:Humans; D008055:Lipids / Q000737:chemistry*; D008081:Liposomes / Q000737:chemistry*; D009181:Mycoses / Q000188:drug therapy* / Q000191:economics
D000935:Antifungal Agents; D008055:Lipids; D008081:Liposomes; D000666:Amphotericin B